Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Share:
Related BMY
Bristol-Myers Squibb Target, Estimates Under Review At Goldman Sachs
Earnings Scheduled For April 28, 2016
Bristol-Myers Hits 17-Year High On Q1 Report; Celgene Also Up (Investor's Business Daily)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA

 

Related Articles (BMY)

View Comments and Join the Discussion!